Articles tagged with Cancer Medication
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
A new study finds that enzalutamide significantly extends life and improves quality of life in men with advanced prostate cancer. The fourth drug in two years to demonstrate this effect, it offers improved treatment options for men with the disease.
Researchers uncover chromosomal translocations that cause cancer, potentially leading to targeted therapies and personalized treatment. The study's findings may enable doctors to offer more accurate prognoses and inform treatment decisions.
Researchers have identified an experimental drug, GSIs, that blocks Notch and prevents lung cancer growth in mice without treatment-related side effects. This discovery brings new clues for the treatment of lung cancer and is being tested in co-clinical trials.
A new method allows for personalized clinical trial predictions by analyzing cell behavior, offering ways to improve cancer treatment outcomes and predict tumor response. The approach may enable oncologists to test combinations of targeted therapies in individual patient tumors.
A blood test detecting high levels of lactate dehydrogenase (LDH) may guide treatment for advanced kidney cancer, extending survival and improving outcomes for patients. Researchers found that LDH levels can predict the effectiveness of mTOR inhibitor temsirolimus in treating late-stage kidney cancer.
Researchers from the University of Cambridge have developed injectable hydrogels that can deliver therapeutics for up to six months, doubling current maximum release time. These hydrogels contain proteins or other therapeutics and are capable of controlled release rate according to material ratio.
Researchers at Case Western Reserve University have identified a new oncogene, FAM83B, which contributes to the development of breast cancer. Elevated expression of this gene is associated with the more aggressive triple-negative subgroup, highlighting the need for new therapeutic options.
A new study has found that patients taking thiazolidinedione (TZD) diabetes drugs are two to three times more likely to develop bladder cancer than those who took sulfonylurea drugs. The risk is especially high among Type 2 diabetes patients, with 170 expected cases per 100,000 treated with TZDs.
A recent pooled analysis of randomized trials found a significant decrease in overall cancer mortality associated with daily aspirin use. The study, which looked at data from over 100,000 participants, found a 37% reduction in overall cancer death risk during a five-year follow-up analysis.
Researchers developed a new prostate cancer screening method that combines drug therapy with changes in PSA levels to identify men with high-risk prostate cancer. The study showed that using PSA with these drugs can help differentiate between prostate cancer and benign disease, even in patients with difficult diagnoses.
Researchers have identified sphingosine kinase as a key player in promoting resistance to breast cancer therapies, such as tamoxifen. Targeted inhibition of SK has shown potential in inducing cell death and blocking tumor growth in drug-resistant models.
Researchers have discovered a new compound with significantly higher anti-HIV activity and improved binding affinity to the CXCR4 receptor. This breakthrough has potential for developing new, more effective drugs against HIV-1 infections and related diseases.
Researchers found several genes in nematode worms that could be potential targets for anti-cancer therapies. By inhibiting these genes, they may reverse key traits associated with cancer cells.
Researchers have developed a method to find and kill malignant cells while sparing healthy ones using theranostic imaging. The technique relies on binding a potent drug therapy to specific proteins on tumor cell surfaces, allowing it to target cancerous cells with precision.
A new method of delivering trastuzumab via subcutaneous injection has been found to be as effective as traditional intravenous delivery, with similar pathologic complete response rates. This could simplify breast cancer treatment, saving time for patients and reducing hospital dependence.
A new clinical trial shows that drinking eight ounces of grapefruit juice daily can increase the levels of an anti-cancer drug called sirolimus in patients with incurable cancer. This combination could help patients avoid serious gastrointestinal side effects and reduce medication costs.
Researchers found a significantly lower risk of life-threatening side-effects in patients taking part in Phase I trials of new-style targeted cancer therapies. The study also identified characteristics that put patients at higher risk, such as being sicker when joining the trial.
A new 'Multi-Hit' mouse model has been developed to study interactions between gene mutations that cause cancer, revealing key findings about the role of Ras and other genes in tumour development. The research suggests that combinations of mutations can lead to cancer, making it a crucial step towards understanding treatment options.
Researchers found two opposing proteins regulating the same set of genes in prostate cancer, suggesting potential therapeutic targets. The study identified genetic markers associated with tumor relapse, which could help predict patient outcomes.
A Kaiser Permanente study found that long-term use of blood pressure medications increasing sun sensitivity is associated with a higher risk of squamous cell lip cancer in non-Hispanic whites. The risk appeared to increase with longer duration of medication use, and was not explained by cigarette smoking.
New human-derived breast cancer models retain heterogeneity, allowing researchers to test drugs more accurately. These models can help identify unique features in individual tumors, enabling targeted treatment.
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center a total of $48.2 million in new grants to support high-impact cancer research and expand access to critical prevention programs across Texas. The awards include funding for seven Multi-Investigator Research Awards and 14 projects to...
Researchers from Netherlands will investigate using DNA analysis to guide personalized cancer treatment, focusing on breast and colorectal tumors. The grant aims to improve patient outcomes by matching patients with the most effective treatments.
Researchers at Michigan State University have identified a key protein called MLK3 that drives breast cancer cell migration and invasion. By targeting this protein, they hope to develop new therapies to prevent the spread of cancer.
Scientists have developed a method to identify new uses for existing medicines, using 11 factors to pair likely drugs with diseases. The 'Train-Match-Fit-Streamline' approach could lead to repurposing of medicines like Celebrex and hookworm treatment for cancer.
A combination of anastrozole and fulvestrant extended the median survival time of women with Stage 4 hormone receptor-positive metastatic breast cancer. The treatment option showed a significant overall survival benefit, particularly exciting for patients who have not had a new treatment in over a decade.
The combination of anastrozole and fulvestrant improved overall survival and progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study showed a six-month extended median survival time compared to anastrozole alone, and improved median time to disease progression.
Researchers have identified a new direction for cancer therapy by discovering a mutant form of the Chk1 gene that permanently stops cancer cell proliferation and causes cell death. This finding has the potential to reduce toxicity in cancer treatment, allowing physicians time to fix genetic errors.
A study published in the New England Journal of Medicine found that combining two drugs extended the lives of women with metastatic breast cancer by more than six months. The combination treatment produced even greater benefits among women who had not previously taken tamoxifen, significantly improving survival rates.
A new approach to treating triple negative breast cancer and clear cell renal cell carcinoma has been discovered by researchers at Mayo Clinic. The approach involves activating a potent tumor suppressor gene called sFRP1, which is silenced in these cancers. Once activated, the laboratory tumor cells stopped growing and died.
Researchers at A*STAR's Institute of Molecular and Cell Biology have devised a fast and cost-saving way to uncover genetic changes associated with cancer. By studying fruit flies, they identified new 'cooperating' genes that work together to cause aggressive cancer.
A new study found that alcohol can make certain medications up to three times more available to the body, effectively tripling their original dose. This is due to ethanol's ability to alter enzyme interactions with a wide range of medications, including those that don't dissolve well in the gastrointestinal tract.
The U.S. Food and Drug Administration has approved several precedent-setting cancer drugs that offer a glimpse into the future of personalized medicine. Companion diagnostics are being used to identify patients most likely to benefit from medication, enabling targeted treatments.
A large international study found that women who give birth at age 30 or older have a reduced risk of endometrial cancer. The risk decreases by approximately 13 percentage points for each five-year delay in last births, with the greatest reduction seen among women who give birth between ages 35 and 39.
Researchers developed a new computational method to identify novel connections between genes, drugs and scientists. The approach analyzed large datasets to create gene-gene networks, connected co-prescribed drugs and side effects, and identified collaborations.
Researchers suggest using multicellular tumor spheroid (MCTS) models to improve cancer drug discovery, as they more accurately mimic human tumors. MCTS models can help identify specific genetic mutations targeted by drugs and interact with the surrounding environment.
A new study reveals that hundreds of random mutations in leukemia cells are linked to aging, not cancer. Researchers found that even healthy individuals accumulate genetic changes over time, which can increase the risk of developing acute myeloid leukemia (AML).
A recent study found that hormone-suppressing drugs reduce oestrogen levels in obese women, but their levels remain more than double those of normal-weight women. This suggests that overweight and obese women may benefit from changes to their treatment, highlighting the need for personalized care.
A new suite of web-based tools, CellMiner, provides researchers with improved capacity to compare data from genomic information against thousands of drugs. By comparing drugs and genetic targets, researchers can identify pharmaceuticals that could be effective against different forms of cancer.
Researchers discovered an uncommon mutation of the BRAF gene in melanoma patients that responds to MEK inhibitor drugs. The BRAF L597 mutation is adjacent to the V600 mutation and was found in 4% of tumor samples, suggesting potential benefits from MEK inhibitors.
A new immunotherapy using nanolipogels (NLGs) delays tumor growth, sends tumors into remission, and increases survival rates in mice. The NLGs deliver two components: an inhibitor drug that counters TGF-β and interleukin-2 to boost the immune response.
A study published in Leukemia & Lymphoma reveals that IDH mutations drive the production of 2-hydroxyglutarate, leading to abnormal gene regulation and increased risk of relapse. Researchers believe targeting IDH mutations may hold promise for treating AML.
TGen researchers will identify genetic differences in glioblastoma patients using whole genome sequencing, with the goal of developing personalized clinical trials. The foundation's funding supports two five-year projects aimed at extending patient survival and improving treatment outcomes.
A new approach using an HIV drug has significantly reduced the incidence of graft-versus-host disease (GvHD) in bone marrow transplant patients. The treatment redirects immune cells away from vital organs, reducing the risk of GvHD without compromising the patient's ability to fight cancer.
Researchers have found a way to overcome drug resistance in childhood cancer by combining crizotinib with an mTOR inhibitor. This combination has shown promise in treating aggressive neuroblastoma tumors that are resistant to current treatments.
A Harvard researcher predicts that a multi-drug approach could make many cancers 'manageable' by targeting the KRAS gene. This strategy involves using at least two drugs to combat drug resistance, which currently limits targeted therapy's effectiveness.
Research established RNA Polymerase I (Pol I) activity as essential for cancer cell survival, and its inhibition with CX-5461 selectively activates p53 to kill tumors. The drug was shown to be 300 times more potent than non-genotoxic p53 activators.
Researchers are developing a new oral multiple sclerosis drug that targets the molecule miR-326, which stimulates the production of immune system mediators. The drug aims to inhibit miR-326 and block the production of Th17 cells, potentially offering a more convenient treatment option for patients.
Researchers developed a novel anticancer drug called G202 that targets cancer cells by activating a specific protein, sparing healthy tissues. In laboratory studies, G202 reduced human prostate tumors grown in mice by an average of 50% within 30 days, outperforming the chemotherapy drug docetaxel.
Researchers discovered a protein, IGFBP3, that helps stop cancer cell proliferation and found other proteins working together with it. This finding could lead to a therapeutic strategy to reprogram cancer cells into permanent dormancy.
The new proton therapy center will provide highly individualized treatments for cancer patients in the region, including pediatric and adult tumors. The center will be operated by UT Southwestern physicians and staff, with laboratory space for researchers and at least four treatment vaults.
A study found that women using fertility drugs had a reduced risk of breast cancer if they did not conceive a 10-plus week pregnancy, but an increased risk if they did. The study suggests that exposure to the drugs may raise risk by modifying breast tissue remodeling during pregnancy.
Researchers create high-throughput flow-through optical microscope to classify rare breast cancer cells in blood samples, boasting a throughput of 100,000 cells per second. The technology demonstrates real-time identification of rare cancer cells with a record low false-positive rate.
New research suggests that normal cells within the tumor, part of the tumor microenvironment, may supply factors that help cancer cells grow and survive despite anti-cancer drugs. The study found that hepatocyte growth factor (HGF) is linked to BRAF inhibitor drug resistance in melanoma.
A new study published in the Canadian Medical Association Journal found a potential link between the use of pioglitazone, a type of thiazolidinedione diabetes medication, and an increased risk of bladder cancer. Researchers analyzed data from over 2.6 million patients to quantify this association.
Presentations at the Genetics Society of America's Model Organism to Human Biology meeting revealed key findings on cancer genomic pathways. Researchers identified mediators of metastasis and potential drug targets in model organisms such as zebrafish, fruit flies, and roundworms.
A BUSM in vitro study discovered a potent combination therapy for breast cancer, including triple-negative and hormone-refractory cases. The treatment re-expressed imprinted tumor suppressor genes, inhibiting cancer cell growth and promoting death.
Researchers at UCSF have discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug. This discovery may lead to better treatments involving precision medicines that combine Tarceva with new drugs designed to block AXL.
The study published in Science Translational Medicine documents pre-clinical data and rationale for developing G-202 as a potential cancer therapy. G-202, combined with prodrug delivery, is effective at killing fast- and slow-growing cancers by targeting PSMA enzyme.